<DOC>
	<DOCNO>NCT02279082</DOCNO>
	<brief_summary>A multi-center , open-label , safety study DFN-02 Treatment Acute Migraines</brief_summary>
	<brief_title>DFN-02 Open Label Safety Study Patients With Acute Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . Patients history acute migraine ( use International Classification Headache Disorders [ ICHD ] criterion , second edition ) ; 2 . Patients , opinion investigator , willing able : Return study site within 72 hour first use study medication , Record migraine instance use study medication rescue medication patient diary duration study ; 3 . Patients use nasal spray device correctly instruction . 1 . Patients onabotulinumtoxinA ( BotoxÂ® ) botulinum toxin treatment ; history receive treatment 180 day prior screen ; 2 . Patients history stroke transient ischemic attack ( TIA ) ; 3 . Patients history migralepsy concurrent diagnosis seizure disorder ; 4 . Patients differentiate migraine headache tensiontype cluster headache ; 5 . Patients ischemic coronary artery disease ( CAD ; ie , angina pectoris , history myocardial infarction document silent ischemia coronary artery vasospasm , include Prinzmetal 's angina ) ; 6 . Patients WolffParkinsonWhite syndrome arrhythmia associate cardiac accessory conduction pathway disorder ; 7 . Patients uncontrolled hypertension ( screen systolic/diastolic blood pressure &gt; 140/90 mmHg ) ; 8 . Patients peripheral vascular disease ischemic bowel disease ; 9 . Patients take medication illness likely affect physiology nasal mucosa ( ie , patient nasal septum surgery , chronic sinusitis , chronic nasal rhinitis ) . ( Note : Patients acute condition acute sinusitis may rescreened 14 day resolution acute sinusitis . ) ; 10 . Patients abnormal nasal physiology pathology , opinion investigator , would allow objective study accomplish ; 11 . Patients know intolerance nasal spray ; 12 . Patients severe renal impairment ( define serum creatinine &gt; 2 mg/dL ) ; 13 . Patients serum total bilirubin &gt; 2.0 mg/dL ; 14 . Patients serum aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase &gt; 2.5 time upper limit normal ( ULN ) ; 15 . Patients history alcohol substance abuse ( include marijuana medical marijuana ) within 1 year would compromise data collection ; 16 . Patients positive urine drug screen illicit drug prescription drug explain state concomitant medication . ( Positive drug screen marijuana exclusionary . ) : 1 . Patients consume opioids treatment migraine use opioids barbiturate temporarily legitimate medical cause may participate long meet MOH criterion . 2 . Benzodiazepines allow used legitimate medical use . 3 . Chronic use amphetamine treat attention deficit disorder ( ADD ) attention deficit hyperactivity disorder ( ADHD ) relate disorder allow long regimen stable least 3 month prior screen expect remain stable throughout study . Note : For abovementioned condition , site must obtain medical monitor approval . 17 . Patients history current neurological psychiatric impairment , cognitive dysfunction , opinion investigator , would compromise data collection ; 18 . Patients receive treatment investigational drug device within 4 week screen visit participate central nervous system clinical trial 3 month prior screen ; 19 . Patients test positive human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody serology test . 20 . Patients medical condition , judgment investigator medical monitor , would confound objective study ( eg , cancer history [ except basal cell carcinoma ] , systemic lupus erythematosus )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>